Staging and pathological grading systems are convenient, but imperfect predictors of recurrence of head and neck squamous cell carcinoma. Therefore, to identify potential alternative prognostic markers, we investigated the methylation status of the promoter of Sal-like protein 2 (SALL2). SALL2 mRNA expression was absent in 8/9 (88.9%) University of Michigan squamous cell carcinoma cell lines, whereas two nonmalignant cell lines had stable expression. The normalized methylation value of SALL2 in cancer cell lines was significantly higher than in normal cell lines. SALL2 methylation found in 74 of 233 (31.8%) tumor specimens was correlated with the methylation status of both SALL1 and SALL3. SALL2 methylation was not associated with any difference in disease-free survival (DFS). Therefore, the presence of SALL2 methylation was statistically correlated with a decrease in DFS in patients with oral cancer (log-rank test, p = 0.032). Furthermore, it was associated with disease recurrence in 36.2% of oral cancer cases, with an odds ratio of 2.922 (95% confidence interval = 1.198–7.130; p = 0.018) by multivariate Cox proportional hazard regression analysis. This study suggests that cytosine-phosphate- guanosine (CpG) hypermethylation is a likely mechanism of SALL2 inactivation and supports the hypothesis that SALL2 could serve as an important clinical risk assessment.
Get full access to this article
View all access options for this article.
References
1.
AlagaratnamS., LindG.E., KraggerudS.M., LotheR.A., and SkotheimR.I. (2011). The testicular germ cell tumour transcriptome. Int J Androl, 34, e133–e150; discussion e50–e51.
2.
Cancer Genome Atlas Research Network. (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489, 519–525.
3.
ChaiL. (2011). The role of HSAL (SALL) genes in proliferation and differentiation in normal hematopoiesis and leukemogenesis. Transfusion 51 Suppl, 4, 87S–93S.
4.
DasguptaS., DashR., DasS.K., SarkarD., and FisherP.B. (2012). Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. J Cell Physiol, 227, 467–473.
5.
DionneK.R., WarnakulasuriyaS., ZainR.B., and CheongS.C. (2015). Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory. Int J Cancer, 136, 503–515.
6.
E HermosillaV., SalgadoG., RiffoE., EscobarD., HeppM.I., FarkasC., et al. (2018). SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes. Mol Oncol, 12, 1026–1046.
7.
EstiloC.L., O-charoenratP., TalbotS., SocciN.D., CarlsonD.L., GhosseinR., et al. (2009). Oral tongue cancer gene expression profiling: identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9,11.
8.
HermosillaV.E., HeppM.I., EscobarD., FarkasC., RiffoE.N., CastroA.F., et al. (2017). Developmental SALL2 transcription factor: a new player in cancer. Carcinogenesis, 38, 680–690.
9.
HillV.K., HessonL.B., DansranjavinT., DallolA., BiecheI., VacherS., et al. (2010). Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 9,51.
10.
HuangW.Y., HsuS.D., HuangH.Y., SunY.M., ChouC.H., WengS.L., et al. (2015). MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res, 43, D856–D861.
11.
KarantzaliE., LekakisV., IoannouM., HadjimichaelC., PapamatheakisJ., and KretsovaliA. (2011). Sall1 regulates embryonic stem cell differentiation in association with nanog. J Biol Chem, 286, 1037–1045.
12.
KumarB., CordellK.G., LeeJ.S., WordenF.P., PrinceM.E., TranH.H., et al. (2008). EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol, 26, 3128–3137.
13.
LiC.M., GuoM., BorczukA., PowellC.A., WeiM., ThakerH.M., et al. (2002). Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol, 160, 2181–2190.
14.
LinJ., QianJ., YaoD.M., QianW., YangJ., WangC.Z., et al. (2013). Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. Leuk Res, 37, 71–75.
15.
LiuB.H., JobichenC., ChiaC.S.B., ChanT.H.M., TangJ.P., ChungT.X.Y., et al. (2018). Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide. Proc Natl Acad Sci U S A, 115, E7119–E7128.
16.
LiuH., AdlerA.S., SegalE., and ChangH.Y. (2007). A transcriptional program mediating entry into cellular quiescence. PLoS Genet 3,e91.
17.
LuoJ., WangW., TangY., ZhouD., GaoY., ZhangQ., et al. (2017). mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes. J Cancer, 8, 646–656.
18.
MiaoF., ZhangX., CaoY., and WangY. (2017). Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells. BMC Cancer 17,838.
19.
MisawaK., ImaiA., MochizukiD., MimaM., EndoS., MisawaY., et al. (2018b). Association of TET3 epigenetic inactivation with head and neck cancer. Oncotarget, 9, 24480–24493.
20.
MisawaK., MisawaY., ImaiA., MochizukiD., EndoS., MimaM., et al. (2018a). Epigenetic modification of SALL1 as a novel biomarker for the prognosis of early stage head and neck cancer. J Cancer, 9, 941–949.
21.
MisawaK., MochizukiD., ImaiA., MisawaY., EndoS., MimaM., et al. (2017). Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer. Clin Epigenetics 9,64.
22.
MisawaY., MisawaK., KanazawaT., UeharaT., EndoS., MochizukiD., et al. (2014). Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer, 120, 205–213.
23.
NakagawaT., MatsusakaK., MisawaK., OtaS., TakaneK., FukuyoM., et al. (2017). Frequent promoter hypermethylation associated with human papillomavirus infection in pharyngeal cancer. Cancer Lett, 407, 21–31.
24.
NicoleL., SanaviaT., VeroneseN., CappellessoR., LuchiniC., DabrilliP., et al. (2017). Oncofetal gene SALL4 and prognosis in cancer: a systematic review with meta-analysis. Oncotarget, 8, 22968–22979.
25.
NielsenT.O., HsuF.D., O'ConnellJ.X., GilksC.B., SorensenP.H., LinnS., et al. (2003). Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol, 163, 1449–1456.
26.
PanL., LiangW., GuJ., ZangX., HuangZ., ShiH., et al. (2018). Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells. Oncotarget, 9, 1915–1930.
27.
ParkinD.M., BrayF., FerlayJ., and PisaniP. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74–108.
28.
ParrishM., OttT., Lance-JonesC., SchuetzG., Schwaeger-NickolenkoA., and MonaghanA.P. (2004). Loss of the Sall3 gene leads to palate deficiency, abnormalities in cranial nerves, and perinatal lethality. Mol Cell Biol, 24, 7102–7112.
29.
ParrocheP., ToukaM., MansourM., BouvardV., ThepotA., AccardiR., et al. (2011). Human papillomavirus type 16 E6 inhibits p21(WAF1) transcription independently of p53 by inactivating p150(Sal2). Virology, 417, 443–448.
30.
ShaM., MaoG., WangG., ChenY., WuX., and WangZ. (2015). DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. Acta Pharmaceutica Sinica B, 5, 188–193.
31.
ShikauchiY., SaiuraA., KuboT., NiwaY., YamamotoJ., MuraseY., et al. (2009). SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. Mol Cell Biol, 29, 1944–1958.
32.
SungC.K., and YimH. (2015). The tumor suppressor protein p150(Sal2) in carcinogenesis. Tumour Biol, 36, 489–494.
33.
SungC.K., and YimH. (2017). Roles of SALL2 in tumorigenesis. Arch Pharm Res, 40, 146–151.
34.
SungC.K., LiD., AndrewsE., DrapkinR., and BenjaminT. (2013). Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Mol Oncol, 7, 419–427.
35.
TongW.G., WierdaW.G., LinE., KuangS.Q., BekeleB.N., EstrovZ., et al. (2010). Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics, 5, 499–508.
36.
WangH., KohashiK., YoshizumiT., OkumuraY., TanakaY., ShimokawaM., et al. (2017). Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 64, 69–75.
37.
WeiX., ZhangS., CaoD., ZhaoM., ZhangQ., ZhaoJ., et al. (2015). Aberrant hypermethylation of SALL3 with HPV involvement contributes to the carcinogenesis of cervical cancer. PLoS One 10,e0145700.
38.
WhangS.N., FilippovaM., and Duerksen-HughesP. (2015). Recent progress in therapeutic treatments and screening strategies for the prevention and treatment of HPV-associated head and neck cancer. Viruses, 7, 5040–5065.
39.
WolfJ., Muller-DeckerK., FlechtenmacherC., ZhangF., ShahmoradgoliM., MillsG.B., et al. (2014). An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. Oncogene, 33, 4273–4278.
40.
WuZ., ChengK., ShiL., LiZ., NegiH., GaoG., et al. (2015) Sal-like protein 2 upregulates p16 expression through a proximal promoter element. Cancer Sci, 106, 253–261.
41.
YangJ. (2018). SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis. Biomark Res 6,1.
42.
YangX.X., SunJ.Z., LiF.X., WuY.S., DuH.Y., ZhuW., et al. (2012). Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma. World J Gastroenterol, 18, 2719–2726.
43.
ZhangB., BieQ., WuP., ZhangJ., YouB., ShiH., et al. (2018). PGD2/PTGDR2 signaling restricts the self-renewal and tumorigenesis of gastric cancer. Stem Cells, 36, 990–1003.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
